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Polo-like kinase 1 (Plk1) is a key regulator of mitotic progression and cell division in eukaryotes. It is highly expressed
in tumor cells and considered a potential target for cancer therapy. Here, we report the discovery and application of a
novel potent small-molecule inhibitor of mammalian Plk1, ZK-Thiazolidinone (TAL). We have extensively characterized
TAL in vitro and addressed TAL specificity within cells by studying Plk1 functions in sister chromatid separation,
centrosome maturation, and spindle assembly. Moreover, we have used TAL for a detailed analysis of Plk1 in relation to
PICH and PRC1, two prominent interaction partners implicated in spindle assembly checkpoint function and cytokinesis,
respectively. Specifically, we show that Plk1, when inactivated by TAL, spreads over the arms of chromosomes, resem-
bling the localization of its binding partner PICH, and that both proteins are mutually dependent on each other for correct
localization. Finally, we show that Plk1 activity is essential for cleavage furrow formation and ingression, leading to
successful cytokinesis.
INTRODUCTION
The error-free segregation of chromosomes during cell divi-
sion is necessary for the maintenance of correct ploidy and
genomic integrity, and errors in cell division are presumed
to lead to aneuploidy and cancer (Rajagopalan and Len-
gauer, 2004). To ensure that daughter cells receive the cor-
rect complement of chromosomes, two key events need to be
coordinated. First, chromosomes must be equally segre-
gated, a process that depends on the mitotic spindle. Second,
cytokinesis, the process dividing the cell into two, must
occur between the two sets of segregated chromosomes.
Both of these processes require the activity of a key cell cycle
regulator, the Polo-like kinase 1 (Plk1). Plks form a con-
served subfamily of serine/threonine protein kinases. The
first member to be identified was Polo in Drosophila melano-
gaster (Llamazares et al., 1991) and, subsequently, four Plk
family members have been identified in mammals (Glover et
al., 1998; Barr et al., 2004).
Plk1 contains an N-terminal kinase domain and a phos-
phopeptide-binding C-terminal regulatory polo-box domain
(PBD; Leung et al., 2002; Elia et al., 2003b). In vertebrates Plk1
has been implicated in the activation of Cdk1-cyclin B upon
entry into mitosis, centrosome maturation via the recruit-
ment of the -tubulin ring complex (-TuRC), spindle for-
mation, sister chromatid separation by cohesin removal
from the chromosome arms, promotion of anaphase onset
through direct phosphorylation of the APC/C complex as
well as the inhibition of the APC/C inhibitor Emi1, and
finally, mitotic exit and cytokinesis (reviewed in Barr et al.,
2004). Fitting with these diverse functions, Plk1 localizes to
the centrosomes, spindle poles, and kinetochores in
prophase and metaphase, the central spindle in anaphase,
and the midbody during cytokinesis. These localizations
require the function of the PBD (Jang et al., 2002; Seong et al.,
2002) and priming-kinases to generate phosphorylated
docking sites that are subsequently recognized by the PBD
(Elia et al., 2003b). The identification of these priming kinases
is therefore important for understanding how Plk1 activity
is controlled throughout mitosis as well as meiosis. In the
early stages of mitosis, Cdk1 generates Plk1 docking sites
(Elia et al., 2003a,b). In contrast, in anaphase Plk1 is able to
self-prime its docking sites on proteins required for cytoki-
nesis. Based on these findings, a model has been proposed to
explain the temporal and spatial control of Plk1 activity
(Neef et al., 2003, 2007).
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Plk1 is overexpressed in a broad range of human tumors,
and this is associated with poor prognosis in several types of
cancer (Eckerdt et al., 2005; Takai et al., 2005). Its association
with tumorigenesis indicates that Plk1 is an attractive kinase
target for cancer drug development (Strebhardt and Ullrich,
2006). The targeted inactivation of essential kinases is often
carried out by ATP-competitive small-molecule inhibitors
that block their enzymatic activity. Small-molecule inhibi-
tors have been successfully used for the inhibition of Aurora
kinases (Keen and Taylor, 2004) and Cdks (Fischer et al.,
2003). Most recently, efforts to identify new Plk inhibitors
have led to the discovery of several potent inhibitors
(McInnes et al., 2006; Peters et al., 2006; Strebhardt and
Ullrich, 2006; Lansing et al., 2007; Lenart et al., 2007), and
these new tools have been successfully used to study several
aspects of Plk1 function.
Here we identify ZK-Thiazolidinone (TAL) as a novel
ATP-competitive inhibitor of Plk1. Following an extensive
characterization of this new inhibitor in vitro, we have ad-
dressed its specificity within intact cells by systematically
analyzing its ability to counteract the role of Plk1 in previ-
ously established functions, notably sister chromatid sepa-
ration, centrosome maturation, and bipolar spindle assem-
bly. Our results confirm the requirement of Plk1 kinase
activity for all these functions, indicating that TAL acts as a
specific and potent Plk1 inhibitor in vivo. Having estab-
lished TAL specificity, we have then used this novel inhib-
itor to gain further insights into the targeting and regulation
of Plk1 at different times throughout mitosis and cytokinesis.
Specifically, we have explored the relationship between the
catalytic activity of Plk1 and the recently identified Plk1-
interacting checkpoint helicase PICH (Baumman et al., 2007),
and we have used TAL as a potent tool for studying Plk1
function at the central spindle during cytokinesis. Our re-
sults provide strong support for the recently proposed self-
priming model of Plk1 targeting in anaphase cells (Neef et
al., 2007) and help to explain the temporal regulation of Plk1
during mitotic exit and cytokinesis.
MATERIALS AND METHODS
Preparation of TAL Inhibitor
TAL was prepared as described (Schulze et al., 2006). For in vitro and in vivo
experiments TAL was used from a stock solution (10 mM) in dimethyl
sulfoxide (DMSO).
In Vitro Kinase Assays
Recombinant baculoviruses expressing full-length His-tagged Plk1 were pro-
duced using the BaculoGold kit according to manufacturer’s instructions (BD
Biosciences Pharmingen, San Diego, CA). Glutathione S-transferase (GST)-
tagged Plk4 wild type (WT; residues 1–265) and kinase dead (KD; D154A) and
His-tagged Aurora A (Kufer et al., 2002) were purified from E. coli. GST-
tagged Aurora B (Neef et al., 2006) was purified from Sf9 cells. Cdk1 was
obtained commercially (Upstate Biotechnology, Lake Placid, NY). In vitro
phosphorylation reactions on different model substrates were carried out in
BRB80 buffer (Stucke et al., 2004) in the case of Plk1, Plk4, and Cdk1 or a
following described protocol for Aurora A (Kufer et al., 2002). Reactions were
supplemented with 10 M ATP and 2 Ci -32P-ATP (Amersham Pharmacia
Biosciences, Piscataway, NJ). In vitro phosphorylation of Mklp2 was per-
formed using 200 ng of substrate, 10 M ATP and 2 Ci -32P -ATP, in a total
volume of 20 l BRB80 for 30 min at 30°C. Reactions were stopped by the
addition of SDS sample buffer and heating to 95°C. Reactions products were
visualized by SDS-PAGE followed by autoradiography.
To determine the half-maximal growth inhibition (IC50) of Plk1, activity
assays were performed for 90 min at 22°C in presence of serial dilutions of
inhibitor in a total volume of 31 l using casein from bovine milk (Sigma, St.
Louis, MO) as the substrate (0.66 g/ml Plk1, 0.7 M biotinylated casein, 50
mM HEPES, pH 7.5, 10 mM MgCl2, 3 mM MnCl2, 1 mM dithiothreitol, 0.01%
Nonidet P40, 3% DMSO, 0.5 M ATP, and 50 nCi -33P-ATP). Reactions were
terminated by addition of 50 l of SPA suspension (100 M ATP, 10 mM
EDTA, 0.2% Triton X-100, 2.5 mg/ml streptavidin-coated SPA beads [Amer-
sham Pharmacia Biosciences] in phosphate-buffered saline). SPA beads were
allowed to sediment over night at 22°C, and incorporated 33P was determined
using a TopCount scintillation counter (Perkin Elmer-Cetus, Norwalk, CT).
Dose–response curves were used to calculate IC50 values. The same procedure
was followed to test a panel of 93 serine/threonine kinases.
Cell Culture and Synchronization
Human MCF7, NCI-H460, DU145, HeLa S3, mouse B16-F10, and Caco-2 cells
were obtained from the American Type Culture Collection (Manassas, VA).
Cells were grown at 37°C under 5% CO2, either in DMEM (HeLa S3) or in
RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
calf serum and penicillin and streptomycin (100 U/ml and 100 mg/ml,
respectively). Thymidine arrest was performed for 14 h at a concentration of
4 mM. Nocodazole and taxol arrests were performed for 16 h at concentra-
tions of 0.2 g/ml and 1 g/mL, respectively. Cells arrested in metaphase
were obtained by treating cells with 25 M noscapine or 20 M VS-83 for 10 h
and subsequently 2 h with 20 M MG132.
In Vitro Cell Proliferation Assays
Cells were seeded in 96-well plates at 1500 (Caco-2), 3000 (NCI-H460, HeLa),
or 5000 (MCF7, DU 145) cells/well. Cells were allowed to adhere for 24 h and
then fresh growth medium plus serial dilutions of inhibitor compounds were
added. The final concentration of the solvent DMSO was 0.5%. After 4 d of
continuous incubation, the cells were fixed with glutaraldehyde and stained
with crystal violet, and the absorbance was recorded at 595 nm. All measure-
ments were done in quadruplicates. The values were normalized to the
absorbance of solvent-treated cells ( 100%), and the absorbance of a refer-
ence plate, which was fixed at the time point of compound application ( 0%).
IC50 was determined as compound concentration that was required to achieve
50% inhibition of cellular growth.
Fluorescence-activated Cell Sorting Analysis
HeLaS3 (Figure 1C) or HeLaS3 and MCF-7 cells (Supplementary Figure 2)
were incubated with 0.5% DMSO or 1 M TAL at different time points (Figure
1C) or various concentrations of TAL for 24 h (Supplementary Figure 2). Cell
suspensions were fixed with 80% ethanol, permeabilized by treatment for 5
min with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10
g/ml propidium iodide. Cellular DNA content was determined by flow
cytometry using FACSCalibur (BD Biosciences Clontech, San Jose, CA) sys-
tem and CellQuest software (Becton-Dickinson, Lincoln Park, NJ).
Transient Transfection and Small Interfering RNA
Plasmid transfections were performed using FuGENE 6 reagent (Roche Di-
agnostics, Indianapolis, IN) according to manufacturer’s instructions. Small
interfering RNA (siRNA) duplexes were transfected using Oligofectamine
(Invitrogen). In siRNA experiments, BubR1 siRNA duplexes (5-GGAGATC-
CTCTACAAAGGG) were purchased from Qiagen (Hilden, Germany). Plk1,
Mad2, BubR1, Eg5, and PICH (oligo 1) were depleted using previously
published duplexes (Stucke et al., 2004; Hanisch et al., 2006; Baumman et al.,
2007), and the GL2 duplex (Elbashir et al., 2001) was used for control. For
rescue experiments, the Plk1-RNAi plasmid was transfected simultaneously
with myc-Plk1 WT or KD constructs, following established protocols (Ha-
nisch et al., 2006).
Mitotic Chromosome Spreads
HeLa S3 cells were either treated with VS-83 or TAL overnight. Mitotic cells
were collected by shake-off. Chromosome spreads were obtained following
established protocols (Hanisch et al., 2006).
RESULTS
TAL Specifically Inhibits Plk1 In Vitro and In Vivo
Screening of the Schering compound collection for inhibition
of Plk1 kinase activity resulted in the identification of the
Thiazolidinone lead series. The Thiazolidinones represent a
novel chemical class of kinase inhibitors. They do not con-
tain either of three preferred structural motifs of ATP-com-
petitive kinase inhibitors (Perola, 2006) and, in particular,
they are distinct from previously described Plk1 kinase in-
hibitors (Andrews et al., 2004; Davis-Ward et al., 2004; Bearss
et al., 2006; Perola, 2006; Steegmaier et al., 2007). The com-
pound characterized here, ZK-Thiazolidinone (Figure 1A) is
hereafter referred to as TAL. As assayed under specific in
vitro conditions TAL inhibited human Plk1 with an IC50 of
19  12 nM (Supplementary Figure 1B; for assay conditions
see Materials and Methods). When tested against a panel of 93
serine/threonine and tyrosine kinases, the compound
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showed high selectivity for Plk1 (Supplementary Table 1
and Supplementary Figure 1A). The only other kinases
showing significant sensitivity to TAL were the two closest
relatives of Plk1: Plk2 and Plk3, which were inhibited at IC50
of lower than 100 nM (data not shown). In contrast, no
significant inhibition could be seen for Plk4 (Supplementary
Figure 1A). We also tested the ability of TAL to inhibit Plk1
activity using the physiological Plk1 target Mklp2 as a sub-
strate (Neef et al., 2003) and found strong inhibition of
Mklp2 phosphorylation by 250 nM TAL (Figure 1B). Taking
together, these results show that TAL potently and selec-
tively inhibits Plk1 in vitro.
TAL Treatment Results in an Increased Mitotic Index Due
to Checkpoint Activation
Consistent with Plk1 inhibition, TAL inhibited the prolifer-
ation of various human and mouse tumor cell lines with an
IC50 of 0.2–1.3 M (Supplementary Figure 1C). Because Plk1
activity is essential for mitotic progression, we analyzed the
effect of TAL on the cell cycle of HeLa S3 and MCF7 cells by
flow cytometry. Within 24 h of treatment with increasing
concentrations of the compound, TAL induced an accumu-
lation of HeLa S3 and MCF7 cells with a 4N DNA content,
indicative of a G2/M arrest (Supplementary Figure 2). Con-
comitantly, a striking increase in the mitotic index (Supple-
mentary Figure 1D) and an increase in phospho-histone H3
staining (Supplementary Figure 1E) could be observed. At
concentrations above 10 M, increasing cell death was ob-
served, dependent on cell line and duration of exposure
(data not shown), in agreement with the reported effect of
Plk1 depletion in tumor cells (Liu and Erikson, 2003; Liu et
al., 2006). We also tested the reversibility of 1 M TAL
treatment of HeLa S3 cells. After 12 h of treatment, a release
for 12 h into fresh medium readily reversed the G2/M block
(Figure 1C). A mitotic arrest was maintained during a 24 h
treatment, but after 48 h an elevated proportion of cells with
sub-2N DNA content was observed, indicative of cell death
(Figure 1C). Because of the clear accumulation of mitotic
cells in response to 12 h treatment with 1 M TAL (Figure
1C), the absence of cell death and the reversibility of the
block, we used 1 M for 12 h as a standard condition for
most of the following experiments.
The predominant phenotype seen upon depletion of Plk1
is a cell cycle arrest in prometaphase (Sumara et al., 2004;
Van Vugt et al., 2004). In line with these observations, treat-
ment of asynchronously growing HeLa S3 cells with 1 M
Figure 1. TAL inhibits specifically Plk1 and
cause a prometaphase-like mitotic arrest. (A)
Chemical structure of the ATP-competitive ki-
nase inhibitor, ZK-Thiazolidinone (TAL). (B)
Mklp2 was treated with buffer alone (Plk1)
or Plk1 with increasing amounts of TAL and
radioactive ATP for 30 min and then analyzed
by SDS-PAGE and autoradiography ([32P]).
Comassie blue staining showed equal
amounts of Mklp2 in all samples. (C) FACS
analysis was performed in HeLa S3 cells
treated for 24 h with DMSO as a control (1) or
for 12 h, 12 h  12 h release, 24 h, and 48 h
with 1 M TAL (2, 3, 4, and 5, respectively).
The percentage of cells with less than 2N (pre-
G1), 2N (G1 and S), or 4N (G2/M) content are
shown. (D) Mad2-positive staining in a mo-
nopolar cell treated with 1 M TAL. Cells
were stained for Mad2 (red), -tubulin
(green), and DNA was stained with DAPI
(blue). Scale bar, 10 m. (E) Mitotic index from
cells after transfection with GL2, BubR1, and
Mad2 siRNA-oligos for 48 h, treated with ei-
ther DMSO or 1 M TAL for the last 12 h. (300
mitotic cells for each combination, n  2). (F)
Selected live-cell images of HeLa cells express-
ing GFP-tagged Histon-H2B treated with
DMSO or 1 M TAL. Time  0 min indicates
the onset of chromosome condensation.
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TAL resulted in a prometaphase-like arrest characterized by
frequent monopolar spindles and kinetochores that were
positive for Mad2 (Figure 1D), indicating that kinetochores
were either not attached to the spindle or not fully occupied
by microtubules. Depletion of either BubR1 or Mad2, two
key regulators of the spindle assembly checkpoint (SAC),
suppressed the mitotic arrest caused by TAL treatment (Fig-
ure 1E), demonstrating its checkpoint dependence. Live cell
microscopy also confirmed that TAL-treated cells failed to
form a normal metaphase plate and instead arrested with
monopolar spindles, whereas control cells entered anaphase
30 min after nuclear envelope breakdown (Figure 1F and
Supplementary Movies S1 and S2).
TAL Treatment Produces Mitotic Defects Expected for
Plk1 Inhibition
To further validate the specificity of TAL for Plk1 within
living cells, we examined the ability of this compound to
interfere with selected processes that are known to require
Plk1 activity, notably centrosome maturation, sister chroma-
tid cohesion, and spindle formation. These processes have
previously been studied extensively, and they all concern
early stages of mitosis (Barr et al., 2004). Most recently, they
have also been used to validate the specificity of other,
structurally distinct Plk1 inhibitors (McInnes et al., 2006;
Peters et al., 2006; Lansing et al., 2007; Lenart et al., 2007).
The first process we examined is centrosome maturation
at the G2/M transition. At this stage of the cell cycle, addi-
tional -TuRCs are recruited to the centrosome to enhance
microtubule nucleation at the onset of mitosis (Khodjakov
and Rieder, 1999; Palazzo et al., 2000). A role for Plk1 in
centrosome maturation was originally established through
antibody injection (Lane and Nigg, 1996) and more recently
confirmed by siRNA-mediated Plk1 depletion (Sumara et al.,
2004; Hanisch et al., 2006). After treatment of cells with TAL,
-tubulin recruitment to centrosomes (identified by pericen-
trin staining) was clearly impaired (Figure 2A), very similar
to the phenotype seen after depletion of Plk1 (Sumara et al.,
2004; Hanisch et al., 2006). For control, untreated cells or cells
displaying a similar cell cycle arrest phenotype due to inhi-
bition of the kinesin-related motor Eg5 (Blangy et al., 1995)
were analyzed in parallel and found to show normal -tu-
bulin recruitment (Supplementary Figure 3 and Figure 2A).
Interestingly, in TAL-treated cells, Plk1 itself failed to local-
ize to centrosomes (see Figure 5 and Supplementary Figure
4), in agreement with a recent study using the Plk1 inhibitor
BI 2536 (Lenart et al., 2007). In human cells, Plk1 depletion
also impairs the recruitment of Aurora A kinase to the
centrosome (De Luca et al., 2006; Hanisch et al., 2006), which
might provide a plausible explanation for the Aurora A
requirement in centrosome maturation observed in inverte-
brates (Hannak et al., 2001; Berdnik and Knoblich, 2002). The
availability of TAL afforded a unique opportunity to address
the question of whether Plk1 activity is required for Aurora
A recruitment. As shown in Figure 2B, Aurora A failed to
localize to centrosomes in TAL-treated cells, similar to the
phenotype seen in Plk1-depleted cells, but not in untreated
cells or Eg5-depleted cells, analyzed for control (Supplemen-
tary Figure 3 and Figure 2B). Instead, in both TAL-treated
cells and Plk1-depleted cells, Aurora A associated predom-
inantly with spindle microtubules (Figure 2B). Eg5 localiza-
tion was not affected upon TAL treatment (Figure 2C) nor
Figure 2. Centrosome maturation is im-
paired in TAL-treated cells. HeLa S3 cells were
transfected with Eg5 or Plk1 siRNA-oligos for
36 h or treated with 1 M TAL for 12 h and
then stained for -tubulin, Aurora A, or Eg5
(red; A, B, and C, respectively), pericentrin (A
and B), or -tubulin (C; green), and DNA was
stained with DAPI (blue). Scale bar, 10 m.
(D) Lysates from nocodazole- (0.2 g/mL) or
taxol- (1 g/ml) arrested cells, treated with
DMSO or 1 M TAL were used for Western
blot analysis. Membranes were probed for
Plk1, Eg5, -tubulin, Aurora A, and -tubulin
as loading control.
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were the levels of Plk1, Eg5, -tubulin, and Aurora A pro-
teins (Figure 2D). These results not only confirm that Plk1
acts upstream of Aurora A (De Luca et al., 2006; Hanisch et
al., 2006), but further demonstrate that Plk1 activity is re-
quired for Aurora A recruitment to centrosomes.
Most recently, evidence has emerged for additional roles
of Plk1 in spindle formation and maintenance (Sumara et al.,
2004; Peters et al., 2006) as well as in kinetochore-microtu-
bule attachment and chromosome congression (Hanisch et
al., 2006; Lenart et al., 2007). To determine whether Plk1
activity is required for the maintenance of spindle bipolarity,
HeLa S3 cells synchronized to display bipolar spindles (see
Materials and Methods) were treated with TAL and followed
by live cell videomicroscopy over time (Supplementary
Movie S3 and Figure 3A). In parallel, cells were fixed and
stained with anti--tubulin antibodies (Figure 3B). Although
control cells (treated with DMSO solvent only) readily main-
tained bipolar spindles and chromosomes in a metaphase
plate (Figure 3A and data not shown), in TAL-treated cells
bipolar spindles progressively collapsed to yield monopolar
microtubule arrays (Figure 3, B and C), and metaphase
plates became disorganized (Figure 3, A and B). Most likely,
this phenotype results from a shortening of kinetochore
fibers (K-fibers) for the benefit of microtubule bundles that
extend from the spindle pole to the cell periphery (Figure 3B,
60 and 120 min, arrows). These results confirm and extend
those recently reported by Kapoor and colleagues (Peters et
al., 2006) using a chemically distinct Plk1 inhibitor.
To explore the suspected role of Plk1 in K-fiber stabiliza-
tion, K-fibers were stained with anti-HURP antibodies (Sillje
et al., 2006) before and after cold treatment (Rieder and
Borisy, 1981). For comparison, monoastral spindles were
produced in control cells by treatment with VS-83, a small-
molecule inhibitor of Eg5 (Sarli et al., 2005). Although
HURP-positive K-fibers could readily be seen in both VS-83
and TAL-treated cells at time zero (Figure 4A, left), cold
treatment for 20 min virtually abolished HURP staining in
TAL-treated cells but not in VS-83 treated cells (Figure 4A,
right). Furthermore, unlike the situation in VS-83 cells, the
thin and long microtubules observed in TAL-treated cells
did not end at kinetochores, as shown by costaining with
CREST kinetochore serum (Figure 4A, bottom panels). These
data lend strong support to the view that Plk1 activity is
required to maintain stable kinetochore-microtubule inter-
actions.
As a final validation of TAL specificity, we examined a
third well-established function of vertebrate Plk1, namely
the removal of cohesins from the arms of sister chromatids
during prophase (Losada et al., 2002; Sumara et al., 2002;
Losada, 2007) As shown by the analysis of chromosomes
spreads, sister chromatid arms remained paired in cells
treated with TAL, whereas the expected X-shaped chromo-
somes, indicative of arm separation, were seen in control
cells treated with VS-83 (Figure 4B). Collectively, our anal-
ysis of the effect of TAL on centrosome maturation, bipolar
spindle formation, and sister chromatid cohesion demon-
strate that this Plk1 inhibitor produces phenotypes that are
entirely consistent with our current understanding of Plk1
function, lending strong support for its in vivo specificity.
Having established confidence in the reliability of TAL as
a new research tool to study Plk1 function, we next pro-
ceeded to use TAL for a more detailed analysis of Plk1 in
relation to two recently identified interaction partners, no-
tably PICH implicated in SAC function (Baumman et al.,
2007) and PCR1, a putative protein scaffold playing a key
role in cytokinesis (Neef et al., 2007).
Spreading of Plk1 and PICH over Chromatid Arms upon
Plk1 Inactivation
Having identified PICH as a prominent Plk1-interaction
partner and substrate in prometaphase, we took advantage
of TAL to explore the consequences of Plk1 inhibition on the
localization of PICH and Plk1 (Figure 5). To provide controls
with monoastral spindles, Eg5-depleted cells were analyzed
in parallel. On inhibition of Plk1 by TAL, PICH was found to
spread over chromatid arms, similar to the phenotype seen
Figure 3. Plk1 activity is required for bipolar
spindle maintenance. (A) Cells were arrested
with 20 M VS-83 for 12 h and released into 20
M MG132 for 2 h to enrich in metaphase cells.
Then 1 M TAL was added and cells were fol-
lowed by live-cell imaging. Representative stills
from live-cell images of HeLa cells expressing
GFP-tagged Histone-H2B are shown. Time  0
represents the time of addition of the inhibitor.
(B) HeLa S3 cells were arrested with 25 M
noscapine during 10 h and release into 20 M
MG132. After 2-h MG132 arrest, 1 M TAL was
added, and cells were fixed at indicated times
and stained for -tubulin (green), and DNA was
stained with DAPI (blue). Representative im-
ages of phenotypes observed at each time point
are shown. Scale bar, 10 m. (C) Quantification
of mono- or bipolar spindles in TAL-treated
cells; 300 mitotic cells for each data point, n 2.
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in Plk1-depleted cells (Figure 5A). This confirms that Plk1 is
required to remove PICH from chromatid arms (Baumman
et al., 2007) and further demonstrates a requirement for Plk1
activity. Interestingly, when compared with (Eg5 depleted)
control cells, Plk1 itself was also found to spread over chro-
matid arms in response to TAL treatment (Figure 5B), sug-
gesting that Plk1 activity is required to concentrate this
kinase at the kinetochore. To mimic the situation seen in
TAL-treated cells, we overexpressed myc-tagged kinase
dead (Plk1 KD) in Plk1-depleted cells. Cells moderately
overexpressing myc-tagged Plk1 KD showed staining of
chromatid arms very similar to that seen for endogenous
Plk1 in TAL-treated cells, whereas Plk WT analyzed for
control remained concentrated at kinetochores (Supplemen-
tary Figure 4B). These results indicate that Plk1 interacts
with a docking partner on chromatid arms, whose localiza-
tion is sensitive to Plk1 activity.
Because the chromosomal localization of PICH is clearly
controlled by Plk1 (Figure 5A and Baumman et al., 2007), we
considered this protein a likely candidate for the recruitment
of Plk1 over chromatid arms. To test this hypothesis, we first
used TAL to confirm that the electrophoretic mobility shift
seen in PICH during mitotic arrest is due to Plk1 activity
(Figure 5C). Then, we analyzed the influence of PICH de-
pletion on Plk1 localization with or without TAL treatment
(Figure 5D). Compared with DMSO-treated control cells,
where Plk1 was concentrated at kinetochores, TAL induced
the spread of Plk1 over chromatid arms. In contrast, upon
depletion of PICH, TAL treatment no longer induced this
redistribution, demonstrating that PICH is required for relo-
calization of TAL-inactivated Plk1 to chromatid arms (Figure
5D). Collectively, the above data strongly suggest that PICH is
the major Plk1 interaction partner on chromosome arms.
Inhibition of Plk1 Activity by TAL Leads to Cytokinesis
Failure
In the past, it has been difficult to pinpoint a specific role for
Plk1 in postanaphase events, because of multiple require-
ments for this kinase at earlier stages of mitosis. Thus, in the
final series of experiments, we used TAL to explore the
purported role of Plk1 in cytokinesis (Mundt et al., 1997;
Carmena et al., 1998; Nigg, 1998; van Vugt and Medema,
2005). TAL treatment of cells released from an MG132 in-
duced metaphase phase arrest caused extensive multinucle-
ation, confirming the requirement for Plk1 for cell division
(Supplementary Figure 5, A and B). To examine this pheno-
type in more detail, we performed live cell imaging on
asynchronous cultures of HeLa S3 cells treated with TAL. In
cells that were in prophase or prometaphase at the time of
TAL addition, bipolar spindle collapsed into a monopole
(Figure 6A), arguing that TAL exerts its Plk1-inhibitory ef-
fect rapidly after addition. Of the cells showing already
aligned chromosomes when the drug was added, spindle
bipolarity was similarly lost in 30% of cells, whereas 70%
progressed into anaphase and segregated their chromo-
somes normally but then failed to complete cytokinesis,
resulting in binucleation (Figure 6A). This argues that events
early in anaphase are regulated by Plk1 and crucial to ensure
proper cytokinesis. Finally, cells that were already in telo-
phase or cytokinesis at the time of TAL addition completed
normal division (Figure 6A). Careful examination of cells
that had aligned chromosomes at the time of TAL addition
Figure 4. (A) Plk1 activity
is required for K-fiber stabili-
zation and chromatid arm
separation. HeLa S3 cells
were treated for 12 h with 20
M VS-83 or 1 M TAL and
before fixation and perme-
abilization with PTEMF; cells
were incubated for 20 min in
ice-cold growth medium.
Cells were stained for HURP
(far red), CREST (red), and
-tubulin (green), and DNA
was stained with DAPI
(blue). (B) DAPI-stained
chromosome spread pre-
pared from HeLa S3 treated
for 10 h with 20 M VS-83 or
1 M TAL.
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Figure 5. Plk1 and PICH spread over chromatid arms upon TAL addition. (A and B) HeLa S3 cells were transfected with Eg5 or Plk1
siRNA-oligos for 36 h or treated with 1 M TAL for 12 h. Cells were fixed and stained for PICH and Plk1 (A and B, respectively; green),
CREST (red), and DNA (blue). Scale bar, 10 m. (C) Lysates from nocodazole (0.2 g/mL) or taxol (1 g/ml) arrested cells, treated with
DMSO or 1 M TAL were used for Western blot analysis. Membranes were probed for PICH, phospho-H3, cyclin-B, and -tubulin as loading
control. (D) HeLaS3 cells were treated under different conditions: first column, DMSO for 12 h; second column, TAL for 12 h; third column,
PICH-siRNA oligo for 36 h; and fourth column, PICH-siRNA oligo for 36 h together with TAL during the last 12 h. Cells were fixed and
stained for PICH (red) and Plk1 (green), and DNA was stained with DAPI (blue). Scale bar, 10 m.
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Figure 6. Plk1 activity is required for successful cytokinesis. (A) Quantification of the percentage of cells in different stages of mitosis that upon TAL
treatment collapsed into monopolar spindles or went through mitosis completing normal division or failing in cytokinesis. Approximately 100 cells were
counted in two independent experiments performed by live-cell imaging. (B) The failure in cytokinesis with or without furrow ingression was analyzed
and plotted for the cells in metaphase or anaphase from the previous experiment. (C) Representative stills from these movies are shown. Time  0
represents the stage in mitosis at the time of addition of the inhibitor. Top panels, a control cell that progress normally through mitosis (DMSO); bottom
panels, cells that fail in cytokinesis with or without furrow formation and ingression (TAL panels, upper two rows and lower two rows, respectively).
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revealed that most of these cells (70%; Figure 6B) failed to
display cleavage furrow ingression, again indicating an
early requirement for Plk1 activity in this process (Figure 6C,
bottom, upper two rows, and Supplementary Movie S4). In
contrast, cells already in anaphase at the time of TAL addi-
tion mostly showed transient furrow ingression (90%; Fig-
ure 6B), and yet cytokinesis ultimately failed (Figure 6C,
bottom, lower two rows, and Supplementary Movie S5).
The furrowing defects in Plk1-inhibited cells suggested
that some aspects of cleavage furrow formation were im-
paired. We therefore looked at the localization of the RhoA
GTPase, the essential regulator of actomyosin dynamics dur-
ing cytokinesis, and its upstream guanine nucleotide ex-
change factor (GEF) ECT2 to the equatorial cell cortex and
central spindle, respectively. Strikingly, TAL suppressed
RhoA recruitment to the equatorial cell cortex, implying that
Plk1 acts upstream of RhoA (Figure 7A). We then investi-
gated the effects of TAL on ECT2, because the localized
activation of RhoA at the cleavage furrow is dependent on
this GEF (Yuce et al., 2005). This showed that ECT2 was lost
from the central spindle in TAL-treated cells (Figure 7B),
explaining why RhoA is lost from the equatorial cell cortex
and cleavage furrow ingression fails upon Plk1 inhibition.
Plk1 targeting during anaphase has been suggested to
control its localization during anaphase and cytokinesis
through a self-priming feedback mechanism (Neef et al.,
2003, 2007). To further test this hypothesis, we investigated
two Plk1 docking partners at the central spindle required for
cytokinesis, notably the kinesin-6 family motor Mklp2 and
the central spindle microtubule-associated protein PRC1.
Control cells treated with DMSO showed normal staining
for Plk1, Mklp2, and PRC1 (Figure 8A, left). In contrast, after
Plk1 inhibition with TAL the central spindle was highly
disorganized and Plk1 staining was lost during anaphase
and telophase (Supplementary Figure 5C; Figure 8A, right).
This suggests that Plk1 must generate a docking site on its
major central spindle-binding partners. Phosphorylation of
Mklp2 by Plk1 is necessary for Mklp2 function and Plk1
localization to the central spindle in late anaphase and telo-
phase (Neef et al., 2003), but so far the consequences of this
phosphorylation for the Mklp2 localization could not be
addressed. After TAL treatment the central spindle localiza-
tion of Mklp2 was strongly reduced and a more cortical
staining appeared (Figure 8A, right). Because Mklp2 is re-
quired for the relocalization of Aurora B from the kineto-
chores to the central spindle (Gruneberg et al., 2006), we
asked whether the localization of Aurora B was altered in
TAL-treated cells. As shown in Supplementary Figure 5C,
Aurora B also showed a cortical localization after inhibitor
treatment, most likely representing the pool of Aurora B
Figure 7. Plk1 activity is required for proper
furrow ingression. (A and B) Control HeLa
cells (left, DMSO) and cells treated for 30 min
with 1 M TAL (right) were fixed and stained
for RhoA or ECT2 (A and B, respectively;
green), actin (B; red), and DNA (blue). Cells in
early and late anaphase stages are shown in
the control.
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bound to the displaced Mklp2, whereas the central spindle
localization of Aurora B was diminished. PRC1 localization
at the central spindle is also affected in Mklp2-depleted cells
(Neef et al., 2007). Therefore, we analyzed PRC1 localization
after treatment with TAL. After inhibition of Plk1 activity,
PRC1 localized to the disorganized central spindle in early
anaphase (Figure 8A). However, in late anaphase/telophase,
PRC1 failed to form a focused band and spread out along the
entire length of the microtubule bundle (Figure 8A, right),
resembling the localization in Mklp2-depleted cells (Neef et
al., 2007). In addition, very strong microtubule bundles were
observed, resembling the phenotype generated upon deple-
tion of endogenous PRC1 and concomitant rescue with a
docking site mutant of PRC1 (S602A mutant), which is un-
able to bind and localize Plk1 (Neef et al., 2007). Phosphospe-
cific antibodies to this site (pT602) specifically stained the
central spindle in control cells, and this staining was lost
upon Plk1 inhibition (Figure 8A, right), confirming the spe-
cific phosphorylation by Plk1 on this site. In contrast, stain-
ing for Mklp1 and for phospho-S911 Mklp1, an Aurora B
phosphosite (Neef et al., 2006), were comparable with or
without TAL treatment (Figure 8A).
Finally, we used the TAL inhibitor to confirm that the
PRC1-T602 phosphorylation by Plk1 correlates with Plk1
binding in vivo. As shown previously, Plk1 and PRC1 did
not interact in metaphase (Figure 8B, 0 min nocodazole
release), when PRC1 is phosphorylated at T481 by Cdk1
(Neef et al., 2007). After 80-min release from nocodazole,
cells entered anaphase, as shown by the dephosphorylation
of PRC1 at T481and the phosphorylation at PRC1 T602 by
Plk1. In these anaphase cells, Plk1 precipitated with PRC1.
However, when the release was performed in the presence
of TAL, T602 was not phosphorylated and the amount of
Plk1 precipitated together with PRC1 was significantly re-
Figure 8. Plk1 activity is required for its in-
teraction with the anaphase spindle. (A) Con-
trol HeLa cells treated for 30 min with DMSO
(left) or 1 M TAL (right) were fixed and
stained for the indicated antibodies. PRC1,
PRC1-pT602, Mklp2, Mklp1, and Mklp1-pS911
are shown in green, Plk1 in red, and DNA in
blue. (B) HeLa cells were arrested in nocoda-
zole (50 ng/ml) for 14 h, then washed, and
released in fresh medium for 80 min. After
20-min release, the inhibitor was added to
sample three to a final concentration of 1 M
and incubated for additional 60 min. PRC1
was precipitated from the lysates with a spe-
cific antibody, and the precipitates were ana-
lyzed by Western blot with antibodies to
PRC1pT481, PRC1pT602, and Plk1. The same
blot was reprobed for total PRC1. The asterisk
shows a cross-reactive band of the PRC1pT602
antibody.
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duced. Together with the previously reported data this
shows that active Plk1 is required for the generation of its
own binding site on PRC1 in anaphase. Thus, the use of TAL
in the above experiments provides strong support for the
previously proposed self-priming model (Neef et al., 2003,
2007).
DISCUSSION
Specific Inhibition of Plk1 by TAL In Vitro and In Vivo
Here we have characterized TAL, a new potent and specific
inhibitor of Plk1. Importantly, TAL is built on a novel chem-
ical scaffold and structurally distinct from other Plk1 inhib-
itors recently described (McInnes et al., 2006; Peters et al.,
2006; Lansing et al., 2007; Lenart et al., 2007). Because spec-
ificity is a general concern when using small molecule in-
hibitors to study biological processes, results can be viewed
with increased confidence whenever chemically distinct
compounds produce consistent phenotypes. Using TAL, we
have been able to confirm functions previously attributed to
Plk1, attesting to the selectivity of this compound. In addi-
tion, the use of TAL has allowed us to enhance our under-
standing of Plk1 function in mitotic spindle formation, chro-
mosome arm separation, and the temporal and spatial
control of Plk1 during mitosis and cytokinesis. These find-
ings are discussed in more detail in the following sections.
Plk1 Activity in Mitotic Spindle Formation and
Chromosome Congression
Bipolar spindle formation and maintenance involves the
remodeling of the microtubule nucleating and organizing
capacities of the spindle poles, as well as proper kineto-
chore-microtubule attachment. Plk1 is involved in both pro-
cesses and may be important to help coordinate these
events. It has previously been shown that Plk1 is needed to
recruit -tubulin to the centrosomes in order to enhance
microtubule nucleation activity in preparation of bipolar
spindle formation (Khodjakov and Rieder, 1999; Palazzo et
al., 2000). Our present study not only confirms that this
function depends on Plk1 activity, but also demonstrates
that Plk1 activity is needed for Aurora A localization to the
centrosomes. This is significant because Aurora A, together
with its partner TPX2, is known to be required for normal
spindle formation (Kufer et al., 2002; Tsai et al., 2003; Eyer
and Maller, 2004). Once mitotic spindles have formed, Plk1
is also required for the maintenance of spindle bipolarity, as
shown by the use of two chemically distinct Plk1 inhibitors
(Peters et al., 2006 and our present study). This intriguing
observation suggests that Plk1 substrates involved initially
in spindle formation must remain phosphorylated and/or
that additional substrates need to be phosphorylated in or-
der to maintain the bipolarity of already formed spindles.
With regard to chromosome congression, our present data
strengthen the emerging view that Plk1 contributes to sta-
bilize kinetochore-microtubule attachments. This may re-
flect a role for Plk1 in the generation of spindle forces that
stabilize kinetochore-microtubule attachments (Sumara et
al., 2004; Hanisch et al., 2006; Lenart et al., 2007), potentially
through direct phosphorylation of Plk1 substrates at the
kinetochore. With the aid of Plk1 inhibitors such as TAL it
should be possible to further address these issues.
Mutual Dependency of Plk1 and PICH in Chromosome
Localization
Two mitotic kinases, Polo-like kinase and Aurora B, have
been implicated in cohesin release during mitotic
prophase (Losada et al., 2002; Sumara et al., 2002). Plk1 can
directly phosphorylate cohesin subunits, but a direct in-
teraction between Plk1 and cohesin has not been reported
and it is not know how phosphorylation leads to the
dissociation of cohesin from chromosomes. Also, other
factors such as Wapl are clearly involved in regulating
cohesin dissociation (Gandhi et al., 2006; Kueng et al.,
2006). Here, we show that Plk1 spread over chromatid
arms when its activity is inhibited with TAL. A similar
redistribution after Plk1 depletion was previously ob-
served for PICH, one of the binding partners of Plk1
during mitosis (Baumman et al., 2007). Our results with
the TAL inhibitor directly link the localization of PICH
over chromatid arms to Plk1 activity. Moreover, our data
clearly demonstrate interdependency between these two
proteins in that Plk1 remains at kinetochores upon TAL
treatment of PICH-depleted cells. Under normal circum-
stances, we envision that Plk1 gets recruited to PICH
(through a Cdk1-dependent priming event) and that a
PICH-Plk1 complex has the ability to spread over chro-
matid arms. Our present results clearly indicate that PICH
is a major interaction partner of Plk1 on chromatid arms
and it will be interesting to explore whether this complex
is mechanistically related to the removal of cohesins by
Plk1. In any case, in response to phosphorylation by Plk1,
PICH is released from chromatid arms, resulting in its
concentration at the centromere/kinetochore (Baumman
et al., 2007).
Temporal Regulation of Plk1 Localization and Activity
Plk1 regulates different processes in a spatially and tempo-
rally controlled manner through its specific recruitment to
different substrates and subcellular structures that have been
phosphorylated by appropriate priming kinases (Elia et al.,
2003a). The prevailing evidence indicates that Cdk1 is a
major priming kinase, albeit not the only one, able to create
Plk1 docking sites (Rauh et al., 2005; Yamaguchi et al., 2005;
Oshimori et al., 2006; Qi et al., 2006; Baumman et al., 2007),
but there is also evidence that Plk1 is itself able to generate
docking sites, particularly during late stages of mitotic pro-
gression when Cdk1 levels have fallen (Neef et al., 2003,
2007). In a recent study, Plk1 levels at both kinetochores and
centrosomes were reported to be strongly reduced in re-
sponse to inhibition of Plk1 activity (Lenart et al., 2007), and
Plk1 has been reported to create a docking site on the kinet-
ochore protein PBIP-1 (Kang et al., 2006). However, after
exposure of cells to TAL we did not observe a strong reduc-
tion in Plk1 levels at kinetochores, although this was difficult
to quantify in view of the spreading of Plk1 over chromatid
arms (see above). In agreement with Peters and coworkers
(Lenart et al., 2007), we also found that the centrosome
localization of Plk1 during early mitosis was sensitive to
Plk1 inhibition by TAL. Potential interaction partners of Plk1
at the centrosome have previously been identified (Casenghi
et al., 2003; Oshimori et al., 2006), and it will be interesting to
explore through what mechanism(s) Plk1 activity is required
for centrosomal localization of this kinase.
Plk1 Function in Cytokinesis
Before the availability of small-molecule inhibitors, defining
the precise roles of Plk1 in cytokinesis was difficult because
of the early prometaphase arrest produced by Plk1 deple-
tion. Using the advantage of chemical inhibitors to block
Plk1 activity in a temporally controlled manner, we show
that the addition of TAL to asynchronously growing cell
populations produces widely different phenotypes, depend-
ing on the exact time of addition. In particular, when cells
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were already about to enter anaphase at the time of TAL
addition, the inhibition of Plk1 abolished both cleavage fur-
row formation and ingression. In contrast, when cells had
already progressed to late anaphase at the time of TAL
addition, furrow formation and partial ingression could be
observed, before furrows regressed and cells failed to un-
dergo cytokinesis. Collectively, these data demonstrate that
the exact cell cycle position is critical for the phenotypic
consequences of Plk1 inhibition.
During anaphase, antiparallel microtubules are bundled by
kinesin motors and microtubules-associated proteins, mainly
PRC1 (reviewed in Glotzer, 2005). Here, we have shown that
TAL treatment causes the disorganization of the central spindle
and concomitant Plk1 displacement, suggesting that this phe-
notype may result from the lack of phosphorylation on the
prominent Plk1-docking partners PRC1 and Mklp2, both of
which have previously been shown to be required for Plk1
recruitment to the central spindle. We further show that Plk1 is
a critical upstream activator of the ECT2-RhoA cascade that is
required to initiate cytokinesis. This conclusion has been con-
firmed independently with other small-molecule inhibitors
(Brennan et al., 2007; Petronckzi et al., 2007) and also through a
chemical genetics approach using an allele-specific Plk1 inhib-
itor (Burkard et al., 2007). Because ECT2 can activate RhoA
globally, additional mechanisms are required to restrict the
equatorial localization of RhoA. Here, we show that TAL treat-
ment inhibits both the localization of ECT2 at the central spin-
dle and the recruitment of RhoA to the equatorial cell cortex in
anaphase. Conceivably, Plk1 may control the localization and
activation of RhoA by directly affecting RhoA itself or its up-
stream regulators, such as CYK-4 and ECT2. Clearly, TAL
represents a useful tool to further explore the role of Plk1 in
cytokinesis and to search for the direct substrates that are
relevant to this process.
The Future of Plk1 Inhibitors
Clearly, Plk1 inhibitors such as the compound TAL de-
scribed here represent powerful research tools. They hold
great promise for the identification and characterization of
new Plk1 substrates at the centrosomes, kinetochores, and
central spindle, and this in turn will help to better under-
stand the spatial and temporal regulation of mitotic progres-
sion and cell division. Whether Plk1 inhibitors will also
prove valuable in a therapeutic context remains to be seen.
Recently, the crystal structure of a Plk1 kinase domain mu-
tant (T210V) in a complex with the nonhydrolyzable ATP
analogue adenylylimidodiphosphate (AMPPNP) has been
reported (Kothe et al., 2007). This and additional structural
information, notably of the kinase domain in either the
active or inhibitor-bound state, will be very helpful for the
optimization of inhibitors, such as to achieve anti-prolifera-
tive effects in tumor cells at submicromolar drug concentra-
tions. Another crucial step toward clinical success will be to
understand how the mitotic arrest caused by the inhibition
of Plk1 is linked to the induction of cell death. Finally, it will
be attractive to monitor potential synergistic effect of Plk1
inhibitors with other compounds that target, for example,
the mitotic spindle apparatus.
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